A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children
A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children
复制标题
DOI：
10.1177/000992289703600801
复制
发表时间：
1997-08-01
影响因子：
1.6
通讯作者：
Lindsay, RN
中科院分区：
文献类型：
--
作者：
Gross, RD;Hoffman, RO;Lindsay, RN
进行了一项研究，以确定局部应用环丙沙星滴眼液在发生急性细菌性结膜炎的儿科人群中的安全性和有效性。已知局部应用的环丙沙星（3 mg/mL）对于患有细菌性结膜炎的成人是安全且有效的治疗;然而，这种广谱氟喹诺酮在儿科患者中的安全性和有效性尚未得到很好的确立。不到1岁）至12岁，来自33个地理位置不同的医疗中心。这些儿童接受0.3%环丙沙星滴眼液（Ciloxan（TM），Alcon Laboratories，沃斯堡，TX）或妥布霉素滴眼液（Tobrex（TM），Alcon Laboratories，沃斯堡，TX）。两种试验药物在第1天和第2天每2小时局部给药一次，然后在第3天至第7天每4小时局部给药一次。在入组前和第7天再次对眼睛进行培养。通过微生物培养数据和医生对总体消退的判断确定的环丙沙星组和妥布霉素组的治疗疗效相似。细菌清除率环丙沙星组为90.1%，妥布霉素组为84.3%（P = 0.29）。第7天临床治愈率分别为87.0%和89.9%（P>0.5）。两种治疗均未发生严重不良事件。
A study was conducted to determine the safety and efficacy of topically applied ciprofloxacin ophthalmic solution in a pediatric population experiencing acute bacterial conjunctivitis. Topically applied ciprofloxacin (3mg/mL) is known to be a safe and effective treatment for adults suffering from bacterial conjunctivitis; however, the safety and effectiveness of this broad-spectrum fluoroquinolone in pediatric patients is not well established, Ciprofloxacin was evaluated in a double-blind, randomized, controlled study of 257 patients ranging from 0 (i.e., less than 1 year) to 12 years of age from 33 geographically diverse medical centers. The children received either 0.3% ciprofloxacin ophthalmic solution (Ciloxan(TM), Alcon Laboratories, Fort Worth, TX) or tobramycin ophthalmic solution (Tobrex(TM), Alcon Laboratories, Fort Worth, TX), Both test medications were administered topically every 2 hours on days 1 and 2 followed by every 4 hours on days 3 through 7, Eyes were cultured prior to enrollment and again on day 7. Treatment efficacy as determined by microbiological culture data and physicians' judgment of overall resolution was similar for the ciprofloxacin and tobramycin groups. Microbiological eradication tvas observed in 90.1% of the ciprofloxacin group and 84.3% of the tobramycin group (P = 0.29). Physicians judged 87.0% of the ciprofloxacin patients and 89.9% of the tobramycin patients clinically cured on day 7 (P>0.5) There were no serious adverse medical events attributable to either treatment, This study showed that topically applied ciprofloxacin ophthalmic solution is safe and effective in a pediatric population experiencing acute bacterial conjunctivitis.